Impact of target vessel on the procedural techniques and outcomes of chronic total occlusion percutaneous coronary intervention.


Journal

The Journal of invasive cardiology
ISSN: 1557-2501
Titre abrégé: J Invasive Cardiol
Pays: United States
ID NLM: 8917477

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 21 11 2023
pubmed: 20 11 2023
entrez: 20 11 2023
Statut: ppublish

Résumé

There is limited information on the impact of the target vessel on the procedural techniques and outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI). We analyzed the baseline clinical and angiographic characteristics and procedural outcomes of 11,580 CTO PCIs performed between 2012 and 2022 at 44 centers. The most common CTO target vessel was the right coronary artery (RCA) (53.1%) followed by the left anterior descending artery (LAD) (26.0%) and the left circumflex artery (LCX) (19.8%). RCA CTOs were longer and more complex, with a higher Japanese CTO score compared with LAD or LCX CTOs. Technical success was higher among LAD (88.8%) lesions when compared with RCA (85.7%) or LCX (85.8%) lesions (P less than .001). The incidence of major adverse cardiovascular events (MACE) was overall 1.9% (n = 220) and was similar among target vessels (P=.916). There was a tendency toward more frequent utilization of the retrograde approach for more proximal occlusions in all 3 target vessels. When compared with all other RCA lesions combined, distal RCA lesions had higher technical success (87.7% vs 85.3%; P=.048). Technical success was similar between various locations of LAD CTOs (P=.704). First/second/third obtuse marginal branch had lower technical success when compared with all other LCX lesion locations (82.7% vs 86.8%; P=.014). There was no association between MACE and CTO location in all 3 target vessels. LAD CTO PCIs had higher technical and procedural success rates among target vessels. The incidence of MACE was similar among target vessels and among various locations within the target vessel.

Sections du résumé

BACKGROUND BACKGROUND
There is limited information on the impact of the target vessel on the procedural techniques and outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
METHODS METHODS
We analyzed the baseline clinical and angiographic characteristics and procedural outcomes of 11,580 CTO PCIs performed between 2012 and 2022 at 44 centers.
RESULTS RESULTS
The most common CTO target vessel was the right coronary artery (RCA) (53.1%) followed by the left anterior descending artery (LAD) (26.0%) and the left circumflex artery (LCX) (19.8%). RCA CTOs were longer and more complex, with a higher Japanese CTO score compared with LAD or LCX CTOs. Technical success was higher among LAD (88.8%) lesions when compared with RCA (85.7%) or LCX (85.8%) lesions (P less than .001). The incidence of major adverse cardiovascular events (MACE) was overall 1.9% (n = 220) and was similar among target vessels (P=.916). There was a tendency toward more frequent utilization of the retrograde approach for more proximal occlusions in all 3 target vessels. When compared with all other RCA lesions combined, distal RCA lesions had higher technical success (87.7% vs 85.3%; P=.048). Technical success was similar between various locations of LAD CTOs (P=.704). First/second/third obtuse marginal branch had lower technical success when compared with all other LCX lesion locations (82.7% vs 86.8%; P=.014). There was no association between MACE and CTO location in all 3 target vessels.
CONCLUSIONS CONCLUSIONS
LAD CTO PCIs had higher technical and procedural success rates among target vessels. The incidence of MACE was similar among target vessels and among various locations within the target vessel.

Identifiants

pubmed: 37983108
doi: 10.25270/jic/23.00139
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Spyridon Kostantinis (S)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Athanasios Rempakos (A)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Bahadir Simsek (B)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Judit Karacsonyi (J)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Salman S Allana (SS)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Khaldoon Alaswad (K)

Henry Ford Cardiovascular Division, Detroit, MI, USA.

Mir Babar Basir (MB)

Henry Ford Cardiovascular Division, Detroit, MI, USA.

Rhian E Davies (RE)

Wellspan York Hospital, York, PA, USA.

Stewart M Benton (SM)

Wellspan York Hospital, York, PA, USA.

Oleg Krestyaninov (O)

Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.

Dmitrii Khelimskii (D)

Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.

Wissam A Jaber (WA)

Emory University Hospital Midtown, Atlanta, GA, USA.

Stephane Rinfret (S)

Emory University Hospital Midtown, Atlanta, GA, USA.

William Nicholson (W)

Emory University Hospital Midtown, Atlanta, GA, USA.

Jarrod Frizzell (J)

The Christ Hospital, Ohio Heart and Vascular, Cincinnati, OH, USA.

Farouc A Jaffer (FA)

Massachusetts General Hospital, Boston, MA, USA.

Jaikirshan J Khatri (JJ)

Cleveland Clinic, Cleveland, OH, USA.

Paul Poommipanit (P)

University Hospitals, Case Western Reserve University, Cleveland, OH, USA.

James W Choi (JW)

Texas Health Presbyterian Hospital, Dallas, TX, USA.

Raj Chandwaney (R)

Oklahoma Heart Institute, Tulsa, OK, USA.

Brian K Jefferson (BK)

Tristar Centennial Medical Center, Nashville, TN, USA.

Taral N Patel (TN)

Tristar Centennial Medical Center, Nashville, TN, USA.

Karim M Al-Azizi (KM)

The Heart Hospital - Plano, Plano, TX, USA.

Srinivasa Potluri (S)

The Heart Hospital - Plano, Plano, TX, USA.

Nazif Aygul (N)

Selcuk University Medical Faculty, Konya, Turkey.

Ahmed M ElGuindy (AM)

Aswan Heart Center, Magdi Yacoub Foundation, Cairo, Egypt.

Nidal Abi Rafeh (N)

North Oaks Health System, Hammond, LA, USA.

Omer Goktekin (O)

Memorial Bahcelievler Hospital, Istanbul, Turkey.

Michaella Alexandrou (M)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Olga C Mastrodemos (OC)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Bavana V Rangan (BV)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Yader Sandoval (Y)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

M Nicholas Burke (MN)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN, USA.

Sevket Gorgulu (S)

Biruni University Medical School, Istanbul, Turkey. E-mail: sevket5@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH